The chart shows that coronary heart disease and stroke are responsible for 27% of total deaths. Both belong to cardiovascular disease. The most common cancer, lung cancer causes 3% of deaths.
The main risk factors for cardiovascular disease are diabetes, hypertension and obesity. It can be assumed that the importance of this disease will be even higher going forward.
But investments in cardiovascular drug development are much lower than in other therapeutic areas. One explanation is the high cost of conducting large cardiovascular trials. The need for successful prevention strategies, access to existing therapies and the development of new innovative drugs offer attractive investment opportunities.
Detecting cancer early on can make such a big difference. The good news is that cancer screening will get much easier in the future.
February was a month of twists and turns for the healthcare industry! From the ebb and flow of macro dynamics to the ups and downs of the Q4 reporting season, healthcare stocks experienced a flurry of activity. Meanwhile, the Medtech, Pharma, and Providers space saw a surge of M&A activity. More in this month’s commentary.
2023 is underway, and with it has come a sense of excitement. The month of January saw a rotation out of the winners and into the laggards of 2022, driven by hopes of a continued disinflationary trend, the FED temporarily pausing its action, growing confidence in a soft landing, a brighter-than-expected European outlook and recent news that the COVID-19 outbreak in China might have reached its peak. Against this backdrop, healthcare stocks lost -0.7%.